Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation

BACKGROUND: Among non-small cell lung cancer (NSCLC) patients with acquired T790 M mutation resistance to first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), 71% are likely to benefit from osimertinib. There have been several reports about the secondary resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Lin-Peng, Chen, Li-Ying, Liao, Xing-Yun, Xu, Zi-Han, Chen, Zheng-Tang, Sun, Jian-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220520/
https://www.ncbi.nlm.nih.gov/pubmed/30400855
http://dx.doi.org/10.1186/s12885-018-4991-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220520/
https://www.ncbi.nlm.nih.gov/pubmed/30400855
http://dx.doi.org/10.1186/s12885-018-4991-4

Ejemplares similares